


Matias Wagner^{a,c}, Malin Zaddach^a, Claudia Nussbaum^d, Geza Berecki^e, Andreas Flemmer^d, Silvana Frizzo^f, Florian Heinen^g, Brian Sparf^h, Martin Staudt^g, Moritz Tacke^a, Markus Wolffb^h, Walid Fazeliⁱ, Steven Petrouf^j, Marcio Souza^f, Ingo Borggraefe^a

^aDivision of Pediatric Neurology, Developmental Medicine and Social Pediatrics, Department of Pediatrics and Comprehensive Epilepsy Center, Ludwig Maximilians University Hospital, Munich, Germany; ^bInstitute of Human Genetics, Technical University of Munich, Munich, Germany; ^cInstitute for Neurogenetics, Helmholtz Centre Munich, German Research Center for Health and Environment (GmbH), Munich, Germany; ^dDivision of Neonatology, Dr. von Hauner Children's Hospital, Ludwig Maximilians University Hospital, Munich, Germany; ^eIon Channels and Human Diseases Group, The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC 3052, Australia; ^fPraxis Precision Medicines, Boston, MA, USA; ^gDepartment of Pediatric Palliative Care, Ludwig Maximilians University Hospital, Munich, Germany; ^hSwiss Epilepsy Center, Klinik Lengg AG, Zürich, Switzerland; ⁱDepartment of Pediatric Neurology, Children's Hospital, University Hospital Bonn, Bonn, Germany

Background

- Early onset SCN2A developmental and epileptic encephalopathy (SCN2A-DEE) is a rare, severe pediatric disorder caused by gain-of-function (GoF) mutations in the SCN2A gene encoding the voltage-gated sodium channel Na_v1.2.¹⁻³
- High risk of premature death and high burden of epileptic seizures, typically beginning within days of birth and difficult to control with anti-seizure medications (ASMs).^{1,4-8}
- Comorbidities include profound global developmental impairment as well as movement disorders, gastrointestinal symptoms, severe irritability, variable sleep problems and frequent hospitalization.^{1,9}
- Drug development efforts for early onset SCN2A-DEE have been scarce.
- Preclinical findings suggest that gapmer antisense oligonucleotides (ASOs) that down regulate SCN2A expression may have potential to alter the disease course in patients.¹⁰



Here, we describe the first clinical experience of intrathecally administered PRAX-222, a novel gapmer ASO, in an infant with early onset SCN2A-DEE and refractory status epilepticus (SE).

Methods

Patient Case Presentation and Eligibility for SCN2A ASO (Elsunersen)

- A preterm infant (29+4 weeks gestation; birthweight 1400g) was diagnosed prenatally (exome sequencing) with the pathogenic SCN2A variant c.3986C>A p.Ala1329Asp (p.A1329D).
- Infant presented with status epilepticus (SE, Fig. 1) and a history of intrauterine seizures and arthrogyposis.
- Anti-seizure treatment with phenobarbital did not reveal any improvement. High-dose treatment with sodium channel blockers (SCB) including phenytoin revealed significant seizure reduction (Fig. 1B); however, seizure reduction was not sustainable even with potentially toxic levels (>40µg/ml, Fig. 4B) of phenytoin.
- Eligibility for elsunersen treatment was evaluated using *in silico* protein structural modeling and *in vitro* electrophysiology studies⁹⁻¹² to ascertain SCN2A GoF status and inform dosing strategies.
- Ongoing safety assessments included ECG, vitals, blood exam, clinical exam, CSF monitoring, cranial ultrasound and MRI.
- Written informed consent of both parents was obtained prior to ASO administration.




Figure 1. Patient Clinical Course in the First 3 Weeks of Life. A) Representative aEEG trace (all aEEG traces shown on this poster comprise 6h of recording) showing a typical sawtooth pattern resembling EEG-status in week 1 of life. B) Seizure reduction after several loading doses of phenytoin (arrow) in week 3 of life. C) Seizure reduction was not sustainable as status pattern reoccurred even with phenytoin levels >40µg/ml. Seizures were subclinical or motor seizures.

Funding: PRAX-222 was made available under an emergency use provision from Praxis Precision Medicines. Medical writing and editorial assistance were provided by Lillian G. Matthews and Jamie Church in accordance with Good Publication Practice (GPP).

Disclosures: SF, RH, HJ, WM, BS, SP and MS are current or former employees/consultants of Praxis Precision Medicines and may be Praxis stockholders.

Variant Characterization and GoF Confirmation

- Voltage clamp experiments confirmed structural modeling predictions that the p.Ala1329Asp variant interferes with binding of the inactivation motif that would lead to GoF via impaired inactivation and increased persistent current.
- Dynamic action potential clamp (DAPC) experiments, performed to assess the impact of the variant on intrinsic neuronal excitability, showed a large increase in action potential firing across the entire input range and significantly reduced rheobase compared to WT.




Figure 2. Location of the A1329D Na_v1.2 Channel Mutation. A) Side and intracellular views of the 3D structure of Na_v1.2 highlighting the A1329 residue (red stick) in the intracellular linker between transmembrane segments S4 and S5 in domain III (S4-S5DM). Note the color-coded four domains (DI-DIV), the inactivation gate (firebrick red), and the β₂ subunit (blue). B) Zoomed-in views of S4-S5DM region, before and after *in silico* mutagenesis (top, WT; bottom, A1329D). The D1329-F1489 interaction is likely to affect the binding of the IFM inactivation motif to its receptor pocket, resulting in delayed inactivation and persistent current.




Figure 3. Biophysical Characteristics of the A1329D Variant and its Impact on Neuronal Excitability Relative to WT. A) Sodium current (I_{Na}) density-voltage relationships (inset voltage protocol). Left: Representative I_{Na} traces. Right: Persistent inward I_{Na} voltage relationships. Left: Representative I_{Na} traces elicited by -10 mV depolarizations. C and D) Voltage dependence of activation and inactivation, respectively. E) Dependence of the time course of I_{Na} inactivation on the membrane potential. Left: Representative WT and A1329D I_{Na} traces elicited by -25 and -5 mV voltages. F) Input-output relationships for WT and A1329D variant. Data presented as mean ± SEM; *p<0.05 vs. WT.

Conclusions

- First-in-patient findings highlight elsunersen's potential as a disease-modifying treatment for early onset SCN2A-DEE.
- Early clinical experience in combination with SCBs indicated safety and a temporal association with seizure reduction, including cessation of previous refractory SE.
- Recent experience of elsunersen in combination with relutrigine demonstrates continued, clinically meaningful improvement alongside previously unattainable reduction in background medications.
- These findings point to elsunersen's potential for enhancement via precision sodium channel modulation addressing residual network hyperexcitability.
- EMBRACE Part A positive topline results position elsunersen as the first potential disease-modifying therapy for early onset SCN2A-DEE, with the ongoing EMBRAVE3 single-arm, registrational study expected to complete in 2026.
- Plans to accelerate development of relutrigine in SCN2A- and SCN8A-DEE following positive EMBOLD interim analysis, with the EMERALD registrational study in broad DEEs underway.

References

- Sanders et al. 2018 Trends Neurosci
- Howell et al. 2015 Neurology
- Howell et al. 2018 Epilepsia
- Ware et al. 2019 Epilepsia Open
- Wolff et al. 2017 Brain
- Wolff et al. 2019 Epilepsia
- Scheffer et al. 2017 Epilepsia
- Zeng et al. 2022 Front Mol Neurosci
- Berecki, Howell et al. 2022 Commun Biol
- Li et al. 2021 J Clin Inv
- Berecki et al. 2018 PNAS
- Pan et al. 2019 Science

First-in-Patient Results Demonstrated Elsunersen Safety and Temporal Association with Seizure Reduction

- Following confirmation of GoF status, treatment with elsunersen initiated when patient was 1 month and 2 weeks old, with 26 doses administered to date (Fig. 4A).
- Elsunersen treatment (intrathecal dosing) in combination with best standard-of-care ASMs (mainly SCBs) was well-tolerated with no drug-related severe or serious adverse events following a 182.5 mg cumulative dose.
- Eight days after first administration, SE was interrupted intermittently and ultimately ceased following continued dosing.
- A >50% reduction in seizure frequency was observed during follow-up, with seizure symptoms being markedly attenuated.
- Longer term follow up from age 9 to 18 months demonstrated stable seizure frequency at ≤5 seizures/hour, maintained after tapering phenytoin at age 14 months.
- Despite some neurodevelopmental progress (i.e. patient switched from nasogastric tube to bottle feeding), neurodevelopment was severely affected at 8 months chronological age; with no further worsening through 2 years of age.




Figure 4. Patient Clinical Course Following Introduction of Elsunersen Treatment Regimen and Effects on Seizures. A) Clinical course including high-dose SCBs and introduction of elsunersen dosing regimen. Associated reduction in seizure frequency is shown (bottom). B) A total of seven elsunersen (intrathecal) doses were administered between 13-Mar-2023 and 29-Sep-2023 (30.5 mg total), with a further 19 doses (8 mg) administered to date (data not shown). C-F) Corresponding aEEG traces. C) Week 7 (1 day before first ASO administration) showing peak seizure frequency (status epilepticus). D-F) Modulation/reduction of seizure activity (often in close timely relationship to SCB administration) 1, 7 and 10 weeks after first administration of elsunersen (D-F, respectively). G) Long term follow up of seizure frequency over 2.5 years. Seizure frequency according to EEG recordings and as reported by parents. Therapy modifications with inclusion of elsunersen and relutrigine are highlighted. NB: seizure exacerbation between July 2nd and 9th (B and G) was due to urosepsis and concomitant decrease of SCB plasma levels.

Adjunctive Relutrigine Demonstrated Continued Clinical Improvement

- Two years after ASO commencement, the treatment strategy was adjusted to include adjunctive precision sodium channel modulation via an emergency use provision for relutrigine (0.5 mg/kg daily dose), with the objective of stabilizing excitability and enhancing clinical outcomes.
- As early as three weeks after relutrigine commencement, parents and nursing staff reported moderate-to-significant improvement including fewer, less severe seizures, with no new safety findings. Continued improvement in clinical status permitted a previously unattainable reduction in carbamazepine dosage.
- As of the most recent evaluation, seizure frequency has decreased to as low as 2 seizures per hour (Fig. 4G), with just one seizure observed during a 2-hour EEG, enabling meaningful parent-child interaction for the first time. Caregiver-reported improvements across multiple domains are presented in Fig. 5.
- Continued improvement in clinical status permitted a reduction in background medications including a previously unattainable reduction in carbamazepine dosage.

CGI-S	CGI-S							
	extremely severe	very severe	quite severe	moderately severe	somewhat severe	little severe	not at all severe	not applicable
Overall	●	●	●	●	●	●	●	●
Epilepsy	●	●	●	●	●	●	●	●
Development	●	●	●	●	●	●	●	●
Gastrointestinal	●	●	●	●	●	●	●	●
Sleep	●	●	●	●	●	●	●	●
Legend	● before start elsunersen	● after 2 weeks of elsunersen	● before start relutrigine	● after 2 months of relutrigine	● after 4 months of relutrigine	●	●	●

CGI-C	CGI-C							
	very much improved	much improved	slightly improved	no change	slightly worse	much worse	very much worse	not applicable
Overall	●	●	●	●	●	●	●	●
Epilepsy	●	●	●	●	●	●	●	●
Development	●	●	●	●	●	●	●	●
Gastrointestinal	●	●	●	●	●	●	●	●
Sleep	●	●	●	●	●	●	●	●
Legend	● before start relutrigine	● after 2 months of relutrigine	● after 4 months of relutrigine	●	●	●	●	●

Figure 5. Caregiver Global Impression of Severity (CGI-S, top) and Change (CGI-C, bottom) at baseline (CGI-S only), after 2 weeks of elsunersen (CGI-S only), before relutrigine commencement (CGI-S only) and after 2 and 4 months of relutrigine (both scales). Findings demonstrate caregiver-perceived improvements in, and reduced severity of, overall disease and individual clinical features. Baseline for CGI-C was before starting relutrigine. The patient has not received elsunersen since summer 2025.

Table 1. Complementary Elsunersen First-in-Patient Clinical Experience: Summary of Findings

First-in-Patient Summary

- Temporal association of elsunersen intrathecal administration with seizure reduction including cessation of status epilepticus in combination with sodium channel blockers
- Seizure reduction was observed as early as 8 days after first administration
- Well tolerated with no drug-related severe or serious adverse events after a 182.5 mg total cumulative dose of elsunersen across 26 doses
- Hammersmith score <10 at 8 months chronological age resembling severe disability; no further worsening through 2 years of age
- Early clinical experience with elsunersen and relutrigine highlighted the potential for complementary precision sodium channel modulation for early onset SCN2A-DEE



Presented at:
American Academy of
Neurology Meeting
18-22 April 2026
Chicago, Illinois

